Avanafil
| Title | Journal |
|---|---|
| An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. | Expert opinion on pharmacotherapy 20130701 |
| Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. | Therapeutic advances in urology 20130201 |
| Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. | Mayo Clinic proceedings 20120901 |
| Re: Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. | The Journal of urology 20120901 |
| Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. | The Journal of urology 20120801 |
| Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: a review of literature. | The journal of spinal cord medicine 20120701 |
| FDA approves new ED remedy. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120601 |
| A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. | The journal of sexual medicine 20120401 |
| Avanafil for the treatment of erectile dysfunction. | Drugs of today (Barcelona, Spain : 1998) 20120101 |
| Avanafil for treatment of erectile dysfunction: review of its potential. | Vascular health and risk management 20120101 |
| cGMP Signaling, Phosphodiesterases and Major Depressive Disorder. | Current neuropharmacology 20111201 |
| Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010). | Expert opinion on therapeutic patents 20111001 |
| Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. | British journal of clinical pharmacology 20110801 |
| Future prospects in the treatment of erectile dysfunction: focus on avanafil. | Drug design, development and therapy 20110101 |
| Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. | Expert opinion on investigational drugs 20101101 |
| Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. | Clinical therapeutics 20100601 |
| Diagnosis and treatment of erectile dysfunction--a practical update. | Journal of medicine and life 20091115 |
| Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. | Psychopharmacology 20090101 |
| Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. | Expert opinion on investigational drugs 20080601 |
| Looking to the future for erectile dysfunction therapies. | Drugs 20080101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040101 |